News
06-01-2013, 04:43 AM
NanoString Technologies, Inc., a privately held provider of life science tools for translational research and molecular diagnostic products, today announced that a clinical study of the Prosigna Breast Cancer Assay will be presented during the Breast Cancer Oral Abstract Session at the 2013 Annual American Society of Clinical Oncology Meeting on Sunday, June 2.
More... (http://www.news-medical.net/news/20130601/NanoString-Technologies-to-present-clinical-study-of-Prosigna-Breast-Cancer-Assay-at-ASCO-2013.aspx)
More... (http://www.news-medical.net/news/20130601/NanoString-Technologies-to-present-clinical-study-of-Prosigna-Breast-Cancer-Assay-at-ASCO-2013.aspx)